⌕
Biohaven · BHVN · NYSE
Tenet — · insufficient data
Compare
$13.24−4.06%At close
$13.24−0.56 (−4.06%)
At close: Nov 17, 2026, 4:00 PM ET· NYSE · USD
Data under review. Our nightly checks found a problem in this company's reported figures on Oct 23, 2026, so we are not showing its score, ratios or statements for now. The figures come back after they pass the checks two nights in a row. The price and chart are live.

Biohaven (BHVN) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● PRNewsWireNov 5, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Biohaven Drives New Research in Graves' Disease: Phase 3 Pivotal Trial with BHV-1300 Underway and Three Scientific Posters at the 2026 American Thyroid Association Annual (ATA) Meeting

Biohaven presents three posters at ATA, highlighting the patient experience, autoimmune biology of disease, and MoDE and TRAP platform, reflecting a research program built around a condition that remains strikingly under…

● PRNewsWireOct 29, 2026 · 16:02 ETCOMPANY'S OWN WORDS
Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results

The US Food and Drug Administration (FDA) accepted new drug application resubmission for Vyglxia (troriluzole) in spinocerebeller ataxia (SCA), user fee goal date 1Q27. Announced exclusive global license with SK Biopharm…

● Zacks Investment ResearchOct 29, 2026 · 10:55 ET
Wall Street Analysts Believe Biohaven Ltd. (BHVN) Could Rally 43.49%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 43.5% in Biohaven Ltd. (BHVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in ea…

● PRNewsWireOct 26, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy

One year after Biohaven's first TRAP degrader, BHV-1400, was highlighted in the Kidney Week opening plenary, Biohaven's second TRAP degrader for kidney disease expands its Yale-licensed platform into a growing nephrology…

● BarronsOct 22, 2026 · 13:29 ET
Biohaven Stock Heads for Best Day in 3 Years as FDA Agrees to Review Drug Again

The Food and Drug Administration agrees to review a New Drug Application for Vyglxia, Biohaven's experimental spinocerebellar ataxia treatment.…

● BenzingaOct 22, 2026 · 10:21 ET
Biohaven Rebounds With FDA Review Date for Rare Disease Drug

Biohaven Ltd. (NYSE:BHVN) stock is surging on Thursday with a session volume of 10.293 million versus an average volume of 2.585 million after an update on the spinocerebellar ataxia (SCA) program.…

● BenzingaOct 8, 2026 · 12:11 ET
Biohaven Expands Asian Licensing Footprint Through Strategic Ono Agreement

Biohaven Ltd. (NYSE:BHVN) entered into a licensing and collaboration agreement with Ono Pharmaceutical Co., Ltd.…

● PRNewsWireOct 8, 2026 · 04:00 ETCOMPANY'S OWN WORDS
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease

Ono will obtain an exclusive license to develop and commercialize Biohaven's MoDE pan IgG degraders in Japan, South Korea, Taiwan, and ASEAN member states, led by BHV-1300 and including certain next-generation follow-on …

● PRNewsWireSep 28, 2026 · 07:30 ET
Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026

Oral presentation selected: Phase 1 findings from the ongoing BHV1530-101 study will be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), a lea…

● PRNewsWireSep 11, 2026 · 18:28 ETCOMPANY'S OWN WORDS
Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)

Biohaven shares gave up nearly 15% in a single session on September 10, 2026 following the FDA's partial clinical hold on new-patient enrollment in the BHV-7000/opakalim epilepsy trials NEW YORK, Sept. 11, 2026 /PRNewswi…

● BarronsSep 10, 2026 · 14:14 ET
Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow.

Biohaven says regulators placed a partial hold on a clinical study for its epilepsy drug candidate, opakalim. One rival drugmaker stands to benefit.…

● BenzingaSep 10, 2026 · 10:43 ET
FDA Pauses New Enrollment for Biohaven Epilepsy Drug Program

Biohaven Ltd. (NYSE:BHVN) on Thursday announced a partial clinical hold issued by the U.S. Food and Drug Administration (FDA) on new patient enrollment for its BHV-7000 program, while maintaining timelines for its lead p…

● ReutersSep 10, 2026 · 07:37 ET
US FDA pauses new enrollment in Biohaven's epilepsy drug trials

Biohaven said on Thursday the U.S. FDA had imposed a partial clinical hold, pausing new patient enrollment in trials of ​its experimental epilepsy drug after rodent findings, sending its ‌shares down more than 13% in pre…

● Defense WorldAug 28, 2026 · 04:12 ET
BlackRock Inc. Invests $196.57 Million in Biohaven Ltd. $BHVN

BlackRock Inc. bought a new stake in shares of Biohaven Ltd. (NYSE: BHVN) during a recent quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional inv…

● The Motley FoolAug 28, 2026 · 03:12 ET
Why Biohaven Stock Was Rocking the Market This Week

Its partner is South Korean peer SK Biopharmaceuticals. It also secured a victory in a lawsuit.…

● Seeking AlphaAug 27, 2026 · 14:21 ET
Biohaven: Buy Reiterated On Opakalim License Agreement For Epilepsy And More

Biohaven Ltd. maintains a Buy rating, driven by pivotal trial progress in protein degraders and a key licensing deal for its Kv7 platform with SK Biopharmaceuticals. BHVN-1300's phase 3 for Graves' disease is underway; B…

● Seeking AlphaAug 27, 2026 · 11:30 ET
Biohaven: Sale Of Opakalim Rights To SK Biopharmaceuticals Makes Sense On Many Levels

Biohaven secures a transformative $795M global licensing deal with SK Biopharmaceuticals for its Kv7 ion channel platform, notably opakalim. This agreement immediately strengthens BHVN's cash position, reduces R&D costs,…

● Zacks Investment ResearchAug 27, 2026 · 10:46 ET
BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program

Biohaven stock rallies 18% on a $795M out-licensing deal granting SK Biopharmaceuticals global rights to its Kv7 epilepsy platform, led by opakalim.…

● BenzingaAug 26, 2026 · 13:41 ET
Why Is Biohaven Stock Soaring Wednesday?

Biohaven Ltd. (NYSE:BHVN) scored two major wins this week. The company signed a lucrative licensing agreement with SK Biopharmaceuticals Co. Ltd. and secured a legal victory alongside Yale University in a trade-secret di…

● ReutersAug 26, 2026 · 02:56 ET
Biohaven licenses epilepsy drug to South Korea's SK Biopharmaceuticals for up to $795 million

Biohaven has ​entered into ‌a licensing agreement ​with ​South Korean drug ⁠maker ​SK Biopharmaceuticals ​for Biohaven's epilepsy drug ​platform, ​including Opakalim, for ‌up ⁠to $795 million, the companies ​said ​in ⁠a …

● PRNewsWireAug 26, 2026 · 02:36 ETCOMPANY'S OWN WORDS
Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

SK Biopharmaceuticals to provide upfront and milestone payments related to the Kv7 platform up to $795 million, along with tiered royalties to Biohaven ranging from the mid-teens to low twenties on U.S. net sales of opak…

● PRNewsWireAug 25, 2026 · 16:41 ET
Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University

NEW HAVEN, Conn., Aug. 25, 2026 /PRNewswire/ -- Biohaven Ltd.…

No upcoming events in the feeds.

NVDA29−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just BHVN · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.